InvestorsHub Logo
Followers 39
Posts 13378
Boards Moderated 1
Alias Born 12/09/2015

Re: drugmanrx post# 11621

Monday, 08/15/2022 9:23:58 PM

Monday, August 15, 2022 9:23:58 PM

Post# of 12520
WTF happened with this BS?

“The selection follows a seven-month formulation development program conducted by Catalent, in which the Active Pharmaceutical Ingredient (API) was screened for ideal formulation conditions, with a number of potential excipients, to come up with a drug product that suits ProtoKinetix’s needs. The efficacy testing will be conducted by EyeCRO of Oklahoma City. This study should be completed by mid to late January 2022.”